Executive Series 27 Jul 16: Viralytics Ltd (VLA) Managing Director, Malcolm McColl

In this short video we discuss: · How trends in cancer treatment are changing from chemo & radiation treatment to methods focussing on the patient’s immune system; · How VLA is using the common cold to help develop cancer treatments; · The strategy VLA intends to apply when commercialising its technology; · Factors that have attracted investors to VLA, resulting in the group becoming a large cap bio-tech by Australian standards; · The VLA roadmap over the course of the next 6 to 12 months.